摘要
目的观察静脉应用唑来膦酸治疗原发性骨质疏松症的疼痛缓解及安全性。方法选取2010年5月至2010年8月原发性骨质疏松症患者50例,静脉滴注唑来膦酸后,观察其疼痛缓解情况,不良反应发生及缓解情况。结果治疗后患者疼痛情况明显缓解(92.0%),治疗后6个月内无新发骨折。用药后不良反应以发热为主要表现(46.0%),患者均可耐受。结论静脉应用唑来膦酸治疗原发性骨质疏松给药方便、依从性好、不良反应轻微,值得临床推广。
Objective To observe the pain relief and safety of intravenous infusion of zoledronic acid for the treatment of primary osteoporosis. Methods Fifty patients with primary osteoporosis were chosen from May 2010 to August 2010. The situation of pain relief and the occurrence and amelioration of adverse effects were observed after intravenous infusion of zoledronic acid. Results The pain was significantly relieved in patients after the treatment （92. 0% ）. And no new fracture happened in 6 months after the treatment. The main adverse reaction after medication was fever （46.0%） , but all patients could tolerate. Conclusion The intravenous infusion of zoledronic acid for the treatment of primary osteoporosis has benefits in convenient administration, good adherence, and minor adverse reaction. It is worthy of promotion in clinic.
出处
《中国骨质疏松杂志》
CAS
CSCD
2011年第12期1092-1094,共3页
Chinese Journal of Osteoporosis
